Moreover, given an adequate number of preexisting active T cells in the Group 1 tumor microenvironment, the balance between CD28/B7 positive and CTLA-4/B7 negative regulatory signals may be overthrown by CTLA-4 blockade, thus evoking excessive immune response and immunity-related toxicity. Here, CD28 is linked to neoplasm.